IL-BRIGHTON-PARK
TheMathCompany, a global data analytics and data engineering firm that partners with companies to enhance their analytics capabilities, today announced that it has secured $50 million in investments. The round of funding was led by Brighton Park Capital, an investment firm that specializes in collaborating with growth-stage software, healthcare, and tech-enabled services businesses. Existing investor, Arihant Patni, also participated in this round. The minority investment will accelerate TheMathCompany’s expansion in the US and EU markets, as well as enhance its next-generation, proprietary platform, Co.dx, which drives value for businesses through analytics at speed and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005153/en/
Founded by industry leaders, Sayandeb Banerjee, Aditya Kumbakonam, and Anuj Krishna, TheMathCompany is a high-growth firm that employs nearly 1,000 data scientists, data engineers, and domain experts. The company represents and partners with Fortune 500 customers across the CPG, Retail, Pharma, Automotive, Technology, and Manufacturing industries in the US, UK, and EU. Enabling clients with a diverse set of capabilities powered by Co.dx, the organization implements data science and engineering initiatives across business functions, including marketing, supply chain, R&D, and finance. TheMathCompany’s hybrid model unifies Co.dx with a comprehensive consulting approach to deliver custom, cutting-edge analytics and AI-driven assets, helping customers implement successful and strategic business decisions.
“ We are thrilled to announce Brighton Park Capital’s investment,” said Sayandeb Banerjee, CEO of TheMathCompany. “The firm’s deep technology sector expertise and proven track record of scaling global enterprises will be instrumental to our growth.”
“We look forward to partnering with TheMathCompany’s founders and the entire team to support their continued growth,” said Mark F. Dzialga, Managing Partner of Brighton Park Capital. “TheMathCompany is positioned for continued success as it strengthens its brand recognition and expands in the US and EU markets, supporting customers on their missions to capture value through data analytics.”
“TheMathCompany is poised to become one of the largest data and analytics consultancies in the world, supported by a world-class team of data engineers and scientists, and complemented by the power of the Co.dx platform to deliver more value, faster, for customers. I couldn’t be more excited to partner with Sayandeb, Aditya, and Anuj on the significant opportunities ahead,” said Jeff Machlin, Partner of Brighton Park. As part of the transaction, Jeff Machlin will join the Board of Directors.
“While most players in the industry have taken decades to grow to our size, we have built this strong foundation within five years. Brighton Park Capital’s partnership will further accelerate our plans to become the world’s leading global analytics consultancy,” said Aditya Kumbakonam, Chief Customer & Growth Officer at TheMathCompany. “As we grow and evolve, this investment will help us continue to bring elevated service and consistent quality to our customers.”
Anuj Krishna, Chief Product Officer at TheMathCompany, said, “With Brighton Park Capital as investors, we are excited to continue creating better opportunities for our people to grow their careers, while expanding the business globally. TheMathCompany will continue to invest heavily in Co.dx – a significant and meaningful differentiator in our journey to help enterprises scale and solve problems faster.”
TheMathCompany employs leading data scientists and engineers globally while also recruiting emerging talent from top-tier universities. New hires participate in a comprehensive onboarding and training program with the company’s in-house growth accelerator, Co.ach. The program is designed to help employees upskill across analytics disciplines and adapt to the industry’s ever-changing dynamics. In addition to fostering continued career development, the firm incentivizes employees with a stock ownership program, enabling them to participate in TheMathCompany’s continued growth and future success.
Avendus Capital served as financial advisor and Shardul Amarchand Mangaldas & Company served as legal counsel to TheMathCompany. Bharucha & Partners and Paul Weiss served as legal counsel to Brighton Park Capital.
About TheMathCompany
TheMathCompany is a global data analytics and data engineering firm that partners with Fortune 500 and equivalent organizations to enhance their analytics capabilities, using IP-led assets, talent, and processes to deliver accelerated and human-centric solutions. TheMathCompany has been recognized as one of the fastest-growing analytics firms in the world and has been featured among global high-growth firms by Nikkei-FT-Statista’s 2021 Growth Champions list, NASSCOM’s AI Gamechangers 2021 report, and the Everest Group’s PEAK Matrix® Assessment 2021. Providing a holistic range of services across data engineering, science, and unique project delivery, the company is disrupting the analytics industry. For more information about TheMathCompany, please visit www.themathcompany.com .
About Brighton Park Capital
Brighton Park is a Greenwich, CT-based investment firm that specializes in software, healthcare, and technology-enabled services. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park, please visit www.bpc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom